Acute Respiratory Distress Syndrome (ARDS)

Respiratory
11
Pipeline Programs
5
Companies
7
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
11
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
8100%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Edesa Biotech
Edesa BiotechON - Markham
4 programs
4
Cohort A: vilobelimabPhase 2Monoclonal Antibody
Cohort A: vilobelimabPhase 2Monoclonal Antibody
Cohort B: paridiprubartPhase 2
Cohort C: bevacizumabPhase 2Monoclonal Antibody
InflaRx
InflaRxJENA, Germany
4 programs
4
Cohort A: vilobelimabPhase 2Monoclonal Antibody1 trial
Cohort A: vilobelimabPhase 2Monoclonal Antibody1 trial
Cohort B: paridiprubartPhase 21 trial
Cohort C: bevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06701682Recruiting200Est. Sep 2028
NCT06703073Recruiting600Est. Sep 2028
NCT06701669Recruiting200Est. Sep 2028
+1 more trials
Genentech
GenentechCA - Oceanside
2 programs
2
Cohort A: vilobelimabPhase 2Monoclonal Antibody
Cohort C: bevacizumabPhase 2Monoclonal Antibody
P
PharmazzIndia - Greater Noida
1 program
1
Normal SalinePhase 21 trial
Active Trials
NCT05241067Not Yet Recruiting80Est. Dec 2026
Bayer
BayerLEVERKUSEN, Germany
2 programs
An ICU admission and a temporally related ARDS diagnosisN/A1 trial
The Association Between IL17, Acute Respiratory Distress Syndrome and Acute Respiratory FailureN/A1 trial
Active Trials
NCT06272942Active Not Recruiting140,000Est. Aug 2025
NCT06779942Completed414Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
PharmazzNormal Saline
InflaRxCohort C: bevacizumab
InflaRxCohort A: vilobelimab
InflaRxCohort B: paridiprubart
InflaRxCohort A: vilobelimab
BayerThe Association Between IL17, Acute Respiratory Distress Syndrome and Acute Respiratory Failure
BayerAn ICU admission and a temporally related ARDS diagnosis

Clinical Trials (7)

Total enrollment: 141,694 patients across 7 trials

NCT05241067PharmazzNormal Saline

Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS

Start: Dec 2025Est. completion: Dec 202680 patients
Phase 2Not Yet Recruiting
NCT06701656InflaRxCohort C: bevacizumab

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

Start: Oct 2025Est. completion: Sep 2028200 patients
Phase 2Recruiting
NCT06701682InflaRxCohort A: vilobelimab

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Start: Jun 2025Est. completion: Sep 2028200 patients
Phase 2Recruiting
NCT06701669InflaRxCohort B: paridiprubart

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Start: Jun 2025Est. completion: Sep 2028200 patients
Phase 2Recruiting
NCT06703073InflaRxCohort A: vilobelimab

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Start: Jun 2025Est. completion: Sep 2028600 patients
Phase 2Recruiting
NCT06779942BayerThe Association Between IL17, Acute Respiratory Distress Syndrome and Acute Respiratory Failure

The Association Between IL17, Acute Respiratory Distress Syndrome and Acute Respiratory Failure

Start: Dec 2024Est. completion: Dec 2024414 patients
N/ACompleted
NCT06272942BayerAn ICU admission and a temporally related ARDS diagnosis

An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States

Start: Jan 2024Est. completion: Aug 2025140,000 patients
N/AActive Not Recruiting

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 141,694 patients
Monoclonal Antibody is the dominant modality (100% of programs)
5 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)